Safety of guselkumab in hepatitis B virus infection

منو

" Safety of guselkumab in hepatitis B virus infection "
Duncan, James Robert; Orlowski, Timothy J.; Elewski, Boni E.

Document Type	:	AL
Record Number	:	924640
Doc. No	:	LA47h636rx
Language of Document	:	English
Main Entry	:	Duncan, James Robert; Orlowski, Timothy J.; Elewski, Boni E.
Title & Author	:	Safety of guselkumab in hepatitis B virus infection [Article]\ Duncan, James Robert; Orlowski, Timothy J.; Elewski, Boni E.
Title of Periodical	:	Dermatology Online Journal
Volume/ Issue Number	:	25/10
Date	:	2019
Abstract	:	Reactivation of hepatitis B virus (HBV) following the use of TNF antagonists has been reported and is a contraindication to use of these medications. Although the risk of reactivation of HBV during use of ustekinumab and secukinumab is low in patients with only HBV core antibody positivity, the risk is substantial in patients with chronic HBV infection. Less information is available regarding the use of pure IL-23 antagonists. Herein we discuss the successful treatment with guselkumab of a patient with HBV core antibody positivity, without evidence of HBV reactivation or other liver complications.